Forward Looking Statements
Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “anticipates”, “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, plans and timelines for the preclinical and clinical development of its product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, the ability to initiate new clinical programs, the risk that the results of current preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical and clinical trials, including those for HB-200, HB-300 HB-400, HB-700 and HB500, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from public health crises, the impact of public health crises on the enrollment of patients and timing of clinical results, and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s Annual Report on Form 10-K for the year ended December 31, 2022 and most recent quarterly report on Form 10-Q, and as well as discussions of potential risks, uncertainties, and other important factors in HOOKIPA’s subsequent filings with the Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com.
Availability of Other Information About HOOKIPA
Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.
HOOKIPA Pharma Inc.
Consolidated Statements of Operations (Unaudited)
(In thousands, except share and per share data)
| | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | (unaudited) | | (unaudited) |
| | 2023 | | 2022 | | 2023 | | 2022 |
Revenue from collaboration and licensing | | $ | 6,867 | | $ | 2,230 | | $ | 12,722 | | $ | 6,421 |
Operating expenses: | | | | | | | | | | | | |
Research and development | | | (24,625) | | | (18,286) | | | (65,262) | | | (51,053) |
General and administrative | | | (4,912) | | | (4,937) | | | (14,259) | | | (14,935) |
Total operating expenses | | | (29,537) | | | (23,223) | | | (79,521) | | | (65,988) |
Loss from operations | | | (22,670) | | | (20,993) | | | (66,799) | | | (59,567) |
Total interest, other income and taxes, net | | | 3,604 | | | 2,713 | | | 10,037 | | | 6,963 |
Net loss | | $ | (19,066) | | $ | (18,280) | | $ | (56,762) | | $ | (52,604) |
Net loss per share — basic and diluted | | | (0.17) | | | (0.25) | | | (0.64) | | | (0.83) |
Condensed Balance Sheets (Unaudited)
(In thousands)
| | | | | | |
| | As of | | As of |
| | September 30, | | December 31, |
| | 2023 | | 2022 |
Cash, cash equivalents and restricted cash | | $ | 108,095 | | $ | 113,444 |
Total assets | | | 164,010 | | | 170,454 |
Total liabilities | | | 68,959 | | | 67,937 |
Total stockholders’ equity | | | 95,051 | | | 102,517 |
